Financial Comparison: Zenas Biopharma (ZBIO) & Its Peers

Zenas Biopharma (NASDAQ:ZBIO) is one of 422 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Zenas Biopharma to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, dividends, earnings, profitability and valuation.

Earnings & Valuation

This table compares Zenas Biopharma and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zenas Biopharma	$5.00 million	N/A	-2.30
Zenas Biopharma Competitors	$154.14 million	-$11.26 million	-56.86

Zenas Biopharma’s rivals have higher revenue, but lower earnings than Zenas Biopharma. Zenas Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Dividends

Zenas Biopharma pays an annual dividend of $0.05 per share and has a dividend yield of 0.6%. Zenas Biopharma pays out -1.4% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 4.5% and pay out 119.0% of their earnings in the form of a dividend.

Profitability

This table compares Zenas Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas Biopharma	N/A	N/A	N/A
Zenas Biopharma Competitors	-14,682.20%	39.10%	-32.41%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Zenas Biopharma and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas Biopharma	0	0	2	0	3.00
Zenas Biopharma Competitors	826	2266	4730	56	2.51

Zenas Biopharma currently has a consensus price target of $40.00, suggesting a potential upside of 389.60%. As a group, “Biotechnology” companies have a potential upside of 49.72%. Given Zenas Biopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Zenas Biopharma is more favorable than its rivals.

Institutional & Insider Ownership

29.3% of shares of all “Biotechnology” companies are owned by institutional investors. 22.5% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Zenas Biopharma beats its rivals on 7 of the 13 factors compared.

About Zenas Biopharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.